Avid Bioservices Inc (NASDAQ: CDMO)’s stock price has increased by 0.09 compared to its previous closing price of 12.36. However, the company has seen a 1.15% increase in its stock price over the last five trading sessions. accesswire.com reported 2024-12-18 that NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. (“Avid”) (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CDMO.
Is It Worth Investing in Avid Bioservices Inc (NASDAQ: CDMO) Right Now?
CDMO has 36-month beta value of 1.41. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CDMO is 63.22M, and currently, short sellers hold a 18.41% ratio of that float. The average trading volume of CDMO on December 18, 2024 was 1.88M shares.
CDMO’s Market Performance
CDMO stock saw an increase of 1.15% in the past week, with a monthly gain of 1.73% and a quarterly increase of -0.64%. The volatility ratio for the week is 0.82%, and the volatility levels for the last 30 days are 0.74% for Avid Bioservices Inc (CDMO). The simple moving average for the last 20 days is 0.54% for CDMO stock, with a simple moving average of 32.05% for the last 200 days.
Analysts’ Opinion of CDMO
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see CDMO reach a price target of $20. The rating they have provided for CDMO stocks is “Overweight” according to the report published on March 14th, 2023.
CDMO Trading at 8.33% from the 50-Day Moving Average
After a stumble in the market that brought CDMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.87% of loss for the given period.
Volatility was left at 0.74%, however, over the last 30 days, the volatility rate increased by 0.82%, as shares surge +1.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.52% upper at present.
During the last 5 trading sessions, CDMO rose by +1.14%, which changed the moving average for the period of 200-days by +49.04% in comparison to the 20-day moving average, which settled at $12.30. In addition, Avid Bioservices Inc saw 90.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDMO starting from Kwietniak Matthew R., who sale 119 shares at the price of $10.15 back on Oct 14 ’24. After this action, Kwietniak Matthew R. now owns 25,407 shares of Avid Bioservices Inc, valued at $1,208 using the latest closing price.
Richieri Richard A., the Chief Operations Officer of Avid Bioservices Inc, sale 2,031 shares at $10.05 during a trade that took place back on Oct 10 ’24, which means that Richieri Richard A. is holding 37,704 shares at $20,412 based on the most recent closing price.
Stock Fundamentals for CDMO
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.08 for the gross margin
The net margin for Avid Bioservices Inc stands at -1.01. The total capital return value is set at -0.08. Equity return is now at value -133.29, with -39.04 for asset returns.
Based on Avid Bioservices Inc (CDMO), the company’s capital structure generated 0.82 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 4.59. The interest coverage ratio of the stock is -2.42.
Currently, EBITDA for the company is -11.48 million with net debt to EBITDA at -12.18. When we switch over and look at the enterprise to sales, we see a ratio of 6.4. The receivables turnover for the company is 4.98for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.30.
Conclusion
To put it simply, Avid Bioservices Inc (CDMO) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
